Premium
Lipoxin A 4 Inhibits the Development of Endometriosis in Mice: The Role of Anti‐Inflammation and Anti‐Angiogenesis
Author(s) -
Xu Zhangye,
Zhao Feng,
Lin Feng,
Chen Jinxia,
Huang Yingping
Publication year - 2012
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.2011.01101.x
Subject(s) - endometriosis , angiogenesis , inflammation , matrix metalloproteinase , mmp9 , vascular endothelial growth factor , immunohistochemistry , medicine , endocrinology , immunoassay , chemistry , vegf receptors , downregulation and upregulation , immunology , antibody , biochemistry , gene
Problem To evaluate the effects of the anti‐inflammatory and anti‐angiogenic roles of LXA4 on endometriosis in mice. Method of study Endometriosis was induced in 40 mice and separated into two groups. LXA4 group was administered by LXA4 for 3 weeks. The endometriotic lesions were counted, measured, and identified by pathology. The presence of a panel of pro‐inflammatory factors was assessed by real‐time RT ‐ PCR , and enzyme‐linked immunoassay, the m RNA , protein levels of matrix metalloproteinase ( MMP s), and vascular endothelial growth factor ( VEGF ) were determined by real‐time RT ‐ PCR and immunohistochemistry; the activity of MMP s was evaluated by gelatin zymography. Results Treatment with LXA4 significantly inhibited endometriotic lesion development (13.58 ± 4.01 mm 2 in LXA4 group and 23.20 ± 7.49 mm 2 , P = 0.0002), downregulated pro‐inflammatory factors, suppressed the activity of MMP9 , and reduced the VEGF levels associated with endometriosis in mice. Conclusion LXA4 may inhibit the progression of endometriosis possibly by anti‐inflammation and anti‐angiogenesis.